Tanisha Manoj Arte

Ms. Tanisha Manoj Arte

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EAEmmanuel Adediran
Emmanuel Adediran
TATanisha Manoj Arte
Tanisha Manoj Arte
Dedeepya PasupuletiDedeepya Pasupuleti
Dedeepya Pasupuleti
Sharon VijayanandSharon Vijayanand
Sharon Vijayanand
RSRevanth Singh
Revanth Singh
Martin DSouzaMartin DSouza
Martin DSouza
Background: Influenza virus is one of the major respiratory virus infections that is a global health concern. Although there are already approved vaccines, most are administered via the intramuscular route, which is usually painful, leading to vaccine hesitancy. To this end, exploring the non-invasive, transdermal vaccination route using dissolving microneedles would significantly improve vaccine compliance. Research on innovative vaccine delivery systems, such as antigen-loaded PLGA microparticles, has the potential to pave the way for a broader range of vaccine candidates. Methods: In this proof-of-concept study, a combination of the inactivated influenza A H1N1 virus and inactivated influenza A H3N2 virus were encapsulated in a biodegradable poly (lactic-co-glycolic acid) (PLGA) polymeric matrix within microparticles, which enhanced antigen presentation. The antigen PLGA microparticles were prepared separately using a double emulsion (w/o/w), lyophilized, and characterized. Next, the vaccine microparticles were assessed in vitro in dendritic cells (DC 2.4) for immunogenicity. To explore pain-free transdermal vaccination, the vaccine microparticles were loaded into dissolving microneedles and administered in mice (n = 5). Results: Our vaccination study demonstrated that the microneedle-based vaccine elicited strong humoral responses as demonstrated by high antigen-specific IgA, IgG, IgG1, and IgG2a antibodies in serum samples and IgA in lung supernatant. Further, the vaccine also elicited a strong cellular response as evidenced by high levels of CD4+ and CD8a+ T cells in lymphoid organs such as the lymph nodes and spleen. Conclusion: The delivery of influenza vaccine-loaded PLGA microparticles using microneedles would be beneficial to individuals experiencing needle-phobia, as well as the geriatric and pediatric population.

28 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SSSarthak Shah
Sarthak Shah
PPParth Patel
Parth Patel
AFAmarae Ferguson
Amarae Ferguson
PBPriyal Bagwe
Priyal Bagwe
Akanksha KaleAkanksha Kale
Akanksha Kale
Martin DSouzaMartin DSouza
Martin DSouza
Over the years, research regarding the Zika virus has been steadily increasing. Early immunization for ZIKV is a priority for preventing complications such as microencephaly and Guillain–Barré syndrome (GBS). Unlike traditional vaccination approaches, oral dissolving films (ODFs) or mucoadhesive film technology is an emerging, exciting concept that can be used in the field of pharmaceuticals for vaccine design and formulation development. This attractive and novel method can help patients who suffer from dysphagia as a complication of a disease or syndrome. In this study, we investigated a microparticulate Zika vaccine administered via the buccal route with the help of thin films or oral dissolving films (ODFs) with a prime dose and two booster doses two weeks apart. In vitro, the ODFs displayed excellent physiochemical properties, indicating that the films were good carriers for vaccine microparticles and biocompatible with the buccal mucosa. In vivo results revealed robust humoral (IgG, subtypes IgG1 and IgG2a) and T-cell responses (CD4+/CD8+) for ZIKV-specific immunity. Both the Zika MP vaccine and the adjuvanted Zika MP vaccine affected memory (CD45R/CD27) and intracellular cytokine (TNF-α and IL-6) expression. In this study, ZIKV vaccination via the buccal route with the aid of ODFs demonstrated great promise for the development of pain-free vaccines for infectious diseases.

5 August 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
RSRevanth Singh
Revanth Singh
MGMahek Gulani
Mahek Gulani
SVSharon Vijayanand
Sharon Vijayanand
TATanisha Manoj Arte
Tanisha Manoj Arte
EAEmmanuel Adediran
Emmanuel Adediran
Martin DSouzaMartin DSouza
Martin DSouza
Influenza and SARS-CoV-2 viruses are both responsible for respiratory tract infections that have caused global outbreaks. Due to frequent mutations, the CDC recommends annual COVID-19 vaccination (CDC Staying Up to Date with COVID-19 Vaccines, 2025), and studies confirm the safety of co-administering it with the flu shot (CDC Getting a Flu Vaccine and Other Recommended Vaccines at the Same Time, 2025). A combination vaccine streamlines dual immunization, reducing the need for separate vaccinations. This study evaluates the immune response elicited by an intranasal microparticulate combination multivalent vaccine for Influenza and COVID-19. The intranasal route can generate mucosal antibodies that recognize and inhibit the virus at its point of entry. The nasal mucosa is highly vascularized, consisting of circulating immune cells that drain into lymphatic circulation to generate a systemic immune response. This non-invasive route of administration can also significantly benefit patients with needle phobia and vaccine hesitancy. The inactivated SARS-CoV-2 Omicron and Delta variants, along with the H1N1 and H3N2 variants of Influenza A were encapsulated into separate PLGA (co-polymer of lactic and glycolic acids) microparticle matrices utilizing a double emulsion method. The adjuvanted vaccine microparticles were administered to mice as one primary vaccination followed by one booster dose via the intranasal route. Serum and lung supernatant analysis revealed significantly higher antigen-specific IgA and IgG responses than controls. Isolated lymph nodes and spleens showed increased cytotoxic and helper T-cell activation. The intranasal vaccine effectively elicited a significant immune response which was comparable in relation to the intramuscular control vaccination. This supports the potential of an intranasal microparticulate combination vaccine as an effective, needle-free alternative for simultaneous immunization for Influenza and SARS-CoV-2.

16 September 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MGMahek Anil Gulani
Mahek Anil Gulani
TATanisha Manoj Arte
Tanisha Manoj Arte
AFAmarae Ferguson
Amarae Ferguson
Dedeepya PasupuletiDedeepya Pasupuleti
Dedeepya Pasupuleti
EAEmmanuel Adediran
Emmanuel Adediran
Martin DSouzaMartin DSouza
Martin DSouza
Vaccines remain one of the most powerful tools in modern medicine, having revolutionized public health by preventing millions of deaths and controlling the spread of infectious diseases worldwide. However, conventional needle-based vaccines face several limitations, including pain and discomfort, the need for cold-chain infrastructure, reliance on trained healthcare personnel, risk of cross-contamination, and limited accessibility in low-resource settings. These challenges have spurred the development of non-invasive vaccination approaches that promise safer, more accessible, and patient-friendly immunization. Non-invasive immunizations not only eliminate the need for needles but may also enhance compliance and enable mucosal immune responses. To harness the full potential of these innovative delivery routes, a comprehensive understanding of their formulation strategies and mechanism of action is essential. This review aims to comprehensively discuss recent advancements in oral, intranasal, microneedle, buccal, sublingual, and vaginal vaccinations and highlight their underlying immunological mechanisms, formulation strategies in preclinical studies, examples of marketed products, and ongoing clinical trials.

1 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
TATanisha Manoj Arte
Tanisha Manoj Arte
Smital Rajan PatilSmital Rajan Patil
Smital Rajan Patil
EAEmmanuel Adediran
Emmanuel Adediran
RSRevanth Singh
Revanth Singh
PBPriyal Bagwe
Priyal Bagwe
Martin DSouzaMartin DSouza
Martin DSouza
Background: In recent years, the COVID-19 pandemic has significantly impacted global health, largely driven by the emergence of various genetic mutations within the SARS-CoV-2 virus. Although the pandemic phase has passed, the full extent of the virus’s evolutionary trajectory remains uncertain, highlighting the need for continued research in vaccine development to establish a cross-reactive approach that can effectively address different variants. This proof-of-concept study aimed to assess the effectiveness of microparticulate vaccine delivery through the minimally invasive microneedle route of administration, using a heterologous prime–booster strategy against the SARS-CoV-2 virus. Method: This strategy uses the whole inactivated virus of the Delta variant for the prime dose and the whole inactivated virus of the Omicron variant for the booster dose, with alum as an adjuvant. The formulation of microparticles involves encapsulating the antigens in poly lactic-co-glycolic acid (PLGA) polymer, which provides sustained release and enhances immunogenicity while protecting the antigen. Microparticles were tested for in vitro assays, and characterization included particle size, zeta potential, and encapsulation efficacy. Furthermore, serum was collected post-administration of the vaccine in mice and was tested for antibody levels. Result: In vitro assays confirmed the non-cytotoxicity and the ability of microparticles to activate the immune response of the vaccine particles. Administering this microparticulate vaccine via microneedles has proven effective for delivering vaccines through the skin. We also observed significantly higher antigen-specific antibody levels and cross-reactivity in the strains. Conclusions: Our adjuvanted microparticulate-based heterologous prime–booster vaccine strategy showed cross-reactivity among the strains and was successfully delivered using microneedles.

28 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SSSarthak Shah
Sarthak Shah
PPParth Patel
Parth Patel
PBPriyal Bagwe
Priyal Bagwe
Akanksha KaleAkanksha Kale
Akanksha Kale
AFAmarae Ferguson
Amarae Ferguson
Martin DSouzaMartin DSouza
Martin DSouza
Humans continue to be at risk from the Zika virus. Although there have been significant research advancements regarding Zika, the absence of a vaccine or approved treatment poses further challenges for healthcare providers. In this study, we developed a microparticulate Zika vaccine using an inactivated whole Zika virus as the antigen that can be administered pain-free via intranasal (IN) immunization. These microparticles (MP) were formulated using a double emulsion method developed by our lab. We explored a prime dose and two-booster-dose vaccination strategy using MPL-A® and Alhydrogel® as adjuvants to further stimulate the immune response. MPL-A® induces a Th1-mediated immune response and Alhydrogel® (alum) induces a Th2-mediated immune response. There was a high recovery yield of MPs, less than 5 µm in size, and particle charge of −19.42 ± 0.66 mV. IN immunization of Zika MP vaccine and the adjuvanted Zika MP vaccine showed a robust humoral response as indicated by several antibodies (IgA, IgM, and IgG) and several IgG subtypes (IgG1, IgG2a, and IgG3). Vaccine MP elicited a balance Th1- and Th2-mediated immune response. Immune organs, such as the spleen and lymph nodes, exhibited a significant increase in CD4+ helper and CD8+ cytotoxic T-cell cellular response in both vaccine groups. Zika MP vaccine and adjuvanted Zika MP vaccine displayed a robust memory response (CD27 and CD45R) in the spleen and lymph nodes. Adjuvanted vaccine-induced higher Zika-specific intracellular cytokines than the unadjuvanted vaccine. Our results suggest that more than one dose or multiple doses may be necessary to achieve necessary immunological responses. Compared to unvaccinated mice, the Zika vaccine MP and adjuvanted MP vaccine when administered via intranasal route demonstrated robust humoral, cellular, and memory responses. In this pre-clinical study, we established a pain-free microparticulate Zika vaccine that produced a significant immune response when administered intranasally.